U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT06948292) titled 'Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics' on April 21.
Brief Summary: QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD within the kidney cells, is expected to improve baseline renal function when given over a period of one year . The result of the change in renal function will be compared to control without the medication during that same period .
Study Start Date: March 01, 2023
Study Type: INTERVENTIONAL
Condition:
Chronic Kidney Disease Stages 3-5
Diabetic Kidney Disease
Hypertensive Kidney Disease
Intervention:
DRUG: QRX-3
phase 2B CKD study
...